Denali Therapeutics' ALS Study Fails to Meet Primary Goal; Shares Plunge 19% After Market Close
Daily NewsInvesting.com -- Biopharmaceutical company Denali Therapeutics experienced a 19% decline in after-hours trading following the announcement that its amyotrophic la...
Read More